Kaposi's sarcoma-associated herpesvirus (KSHV) was reported in 2024 to encode v-IPS-1, presented there as the first described viral homologue of the human innate immune adaptor IPS-1/MAVS, encoded in reverse-complement orientation within the ORF73/LANA locus and expressed during lytic replication. Ectopically expressed v-IPS-1 blocks type I interferon induction upstream of TRAF3, destabilizing the adaptors IPS-1 and TRIF while paradoxically stabilizing TRAF3. The molecular mechanism of this bidirectional modulation — direct versus adaptor-mediated interaction with IPS-1 and TRAF3 — and the functional importance of v-IPS-1 during actual lytic KSHV infection, relative to the virus's many other interferon antagonists, remain undetermined. No later study has addressed any part of the question, which therefore remains open. The problem is to mechanistically and functionally characterize v-IPS-1: identify its direct or indirect interactions, explain the selective destabilization of IPS-1/TRIF and stabilization of TRAF3, and establish its contribution to innate immune evasion in lytic infection and pathogenesis.

Background

Kaposi's sarcoma-associated herpesvirus (KSHV, also called HHV-8) is the oncogenic human gammaherpesvirus that causes Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Like all herpesviruses it alternates between latency, in which the genome persists as an episome expressing few genes, and lytic replication, in which the full gene program is expressed and new virus is produced. A major arm of the host antiviral defense is type I interferon (IFN), a cytokine family induced when pattern-recognition receptors detect viral nucleic acids. Cytoplasmic viral RNA is sensed by the RIG-I-like receptor (RLR) family, which signals through the adaptor IPS-1 (IFN-beta promoter stimulator protein 1), also called MAVS, Cardif, or VISA. Toll-like receptors 3 and 4, which sense viral RNA and bacterial lipopolysaccharide respectively, signal through a distinct adaptor, TRIF. Both pathways converge on TRAF3, a scaffold protein that recruits the kinase TBK1 to phosphorylate the transcription factors IRF3 and IRF7, which then induce IFN transcription. IPS-1 bears an N-terminal CARD (caspase-recruitment) domain, a protein–protein interaction module that receives RLR signals, a central proline-rich region containing a TRAF-interacting motif (TIM) that mediates direct binding to TRAF3, and a C-terminal transmembrane helix that anchors it to mitochondria; the IPS-1–TRAF3 interaction itself is required for normal IFN induction. KSHV encodes several interferon antagonists, including the viral interferon regulatory factors (vIRFs), LANA (the latency-associated nuclear antigen encoded by ORF73), and ORF10, which blocks signaling through the type I IFN receptor. In 2024, Miranda and colleagues reported that KSHV also encodes a previously undescribed open reading frame, in reverse-complement orientation within the ORF73/LANA locus, with homology to the proline-rich region and TIM of human IPS-1 but lacking the CARD and transmembrane domains; they named it viral IPS-1 (v-IPS-1). This homologue and its interaction with TRAF3 had been reported earlier by the same group in a 2018 meeting abstract (ref 2); the 2024 report is the superseding, fuller account, and the direct-versus-adaptor-mediated mechanism of the opposing stability effects and the functional importance of v-IPS-1 during infection remained unresolved. Using a custom antibody, they detected v-IPS-1 protein only in cells entering lytic replication (cells positive for ORF59, a viral DNA polymerase processivity factor expressed only during lytic replication, in TREx-RTA BCBL-1 cells — a primary effusion lymphoma B-cell line carrying latent KSHV in which RTA, the viral lytic switch transactivator, can be induced with doxycycline); in separate experiments with plasmid-transfected HEK293T cells, the detected v-IPS-1 product (~35 kDa) was smaller than the predicted full-length ORF product, and no transcript has been annotated by any independent KSHV transcriptome study. In plasmid overexpression assays, v-IPS-1 blocked IFN-beta reporter induction downstream of RIG-I, MDA5, IPS-1, and TRIF, but not downstream of TBK1, IRF3, or IRF7, and did not block signaling by exogenous IFN — placing its action at or upstream of TRAF3. Expression of v-IPS-1 destabilized IPS-1 (and TRIF) while stabilizing TRAF3 roughly 7-fold. Prior work establishes that the IPS-1/MAVS pathway matters for KSHV itself: MAVS restrains KSHV lytic output, host RNAs sensed by RIG-I drive IFN during KSHV infection, and TRAF3 is a pleiotropic regulator also central to B-cell receptor signaling and survival, relevant because KSHV persists in B lymphocytes. The authors state that they have not determined how v-IPS-1 interacts with IPS-1 or TRAF3, whether directly or through other cellular factors, how it produces the opposite stability effects on IPS-1/TRIF versus TRAF3, and that their overexpression system cannot establish the importance of v-IPS-1 in the context of natural infection, where the roles of the virus's other IFN antagonists, the overlapping LANA locus, other TRAF3-dependent processes, and in vivo pathogenesis all remain unaddressed.

Problem Statement

Determine the molecular mechanism by which the KSHV protein v-IPS-1 modulates the RLR and TLR3/4 pathways at the TRAF3 node, and establish whether and how much v-IPS-1 matters for innate immune evasion during lytic KSHV infection. Specifically: (1) does v-IPS-1 interact directly with IPS-1, with TRAF3, with both, or are the effects mediated by other cellular factors, and through what interaction surfaces (the protein carries an IPS-1-like proline-rich region and predicted TIM but no CARD or transmembrane domain); (2) what mechanism accounts for the bidirectional effects — destabilization of the adaptors IPS-1 and TRIF alongside concurrent stabilization of TRAF3; (3) does v-IPS-1 produced during lytic viral replication (rather than from a plasmid overexpression vector) suppress IFN induction, and what is the dynamics of its expression from the reverse-complement ORF73/LANA-overlapping locus; (4) what is the relative contribution of v-IPS-1 to IFN antagonism in infected cells compared with the other KSHV-encoded antagonists (vIRFs, LANA, ORF10), i.e., the functional redundancy or synergy among them, and what consequences does v-IPS-1-mediated TRAF3 modulation have for other TRAF3-dependent processes such as B-cell receptor signaling and lymphocyte survival; and (5) what is the in vivo significance of v-IPS-1 for KSHV pathogenesis in the context of the host immune response. These strands jointly constitute one objective — the complete mechanistic and functional characterization of v-IPS-1 as a viral IPS-1 homologue — with the mechanistic interaction question (1)–(2) and the infection-context importance question (3)–(5) as its two linked halves. The in vivo significance probed by strand (5) cannot be settled with the cell-culture systems used here.

References

  1. Miranda D Jr, He B, Sanchez JC, Sennatti A, Bontemps JR, Tran JT, Tang WS, Sanchez DJ. A Viral-Encoded Homologue of IPS-1 Modulates Innate Immune Signaling During KSHV Lytic Replication. bioRxiv preprint, posted 2024-07-25 (v1). doi:10.1101/2024.07.24.604690. https://www.biorxiv.org/content/10.1101/2024.07.24.604690v1
  2. He B, Sanchez JC, Sanchez DJ. A viral homologue of IPS-1 Interacts with TRAF3 leading to a diminished antiviral state. Journal of Immunology 2018; 200(1 Meeting Abstract Suppl):126.13. doi:10.4049/jimmunol.200.supp.126.13. https://doi.org/10.4049/jimmunol.200.supp.126.13
  3. Shekhar R, O'Grady T, Keil N, Feswick A, Amador DAM, Tibbetts SA, Flemington EK, Renne R. High-density resolution of the Kaposi's sarcoma associated herpesvirus transcriptome identifies novel transcript isoforms generated by long-range transcription and alternative splicing. Nucleic Acids Research 2024; 52(13):7720-7739. doi:10.1093/nar/gkae540. https://doi.org/10.1093/nar/gkae540
  4. Prazsák I, Tombácz D, Fülöp Á, Torma G, Gulyás G, Dörmő Á, Kakuk B, McKenzie Spires L, Toth Z, Boldogkői Z. KSHV 3.0: a state-of-the-art annotation of the Kaposi's sarcoma-associated herpesvirus transcriptome using cross-platform sequencing. mSystems 2024; 9(2):e01007-23. doi:10.1128/msystems.01007-23. https://doi.org/10.1128/msystems.01007-23
  5. Saha SK, Pietras EM, He JQ, Kang JR, Liu SY, Oganesyan G, Shahangian A, Zarnegar B, Shiba TL, Wang Y, Cheng G. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. The EMBO Journal 2006; 25(14):3257-3263. doi:10.1038/sj.emboj.7601220. https://doi.org/10.1038/sj.emboj.7601220
  6. West JA, Wicks M, Gregory SM, Chugh P, Jacobs SR, Zhang Z, Host KM, Dittmer DP, Damania B. An Important Role for Mitochondrial Antiviral Signaling Protein in the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle. Journal of Virology 2014; 88(10):5778-5787. doi:10.1128/JVI.03226-13. https://doi.org/10.1128/JVI.03226-13
  7. Bisson SA, Page AL, Ganem D. A Kaposi's Sarcoma-Associated Herpesvirus Protein That Forms Inhibitory Complexes with Type I Interferon Receptor Subunits, Jak and STAT Proteins, and Blocks Interferon-Mediated Signal Transduction. Journal of Virology 2009; 83(10):5056-5066. doi:10.1128/JVI.02516-08. https://doi.org/10.1128/JVI.02516-08
  8. Zhao Y, Ye X, Dunker W, Song Y, Karijolich J. RIG-I like receptor sensing of host RNAs facilitates the cell-intrinsic immune response to KSHV infection. Nature Communications 2018; 9:4841. doi:10.1038/s41467-018-07314-7. https://doi.org/10.1038/s41467-018-07314-7